Children and adolescents treated with fremanezumab experienced fewer migraine and headache days compared with placebo, according to an abstract presented at the American Academy of Neurology Annual ...

Estrogen-containing combined hormonal contraceptives are not tied to vascular risk, such as stroke, in women with migraine ...

The FDA has granted marketing authorization to CT-132 for the preventive treatment of episodic migraine in patients aged 18 years and older.

FDA Cleared Nerivio® REN Wearable Offers Non-Drug Treatment Option for Millions of People With Migraine as Young as 8. NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- For millions o ...

Migraine with aura plays a key role in young adults with unexplained stroke, particularly in women, highlighting the need to ...

Dr Ritu Jha Headaches are quite common. However, not all types of headaches are similar. It is important to understand ...

Migraine disease affects millions of Americans, but treatments often cause side effects that hinder sufferers' ability to function.

The FDA has granted marketing authorization to CT-132, an adjunctive, prescription digital therapeutic for the preventive treatment of episodic migraine.

Migraine is the third most common illness in the world, with about 14 percent of the global population experiencing migraine ...

The US Food and Drug Administration (FDA) has approved Click Therapeutics’ CT-132 as the first prescription digital ...

SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned. ZTlido ® is a registered ...